These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 34521417

  • 1. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, Ohte N, Yamada H, Sata M, Node K, CANDLE Trial Investigators.
    Cardiovasc Diabetol; 2021 Sep 14; 20(1):186. PubMed ID: 34521417
    [Abstract] [Full Text] [Related]

  • 2. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A, Toyoda S, Imai T, Shiina K, Tomiyama H, Matsuzawa Y, Okumura T, Kanzaki Y, Onishi K, Kiyosue A, Nishino M, Sakata Y, Node K, CANDLE trial investigators.
    Cardiovasc Diabetol; 2021 Sep 03; 20(1):175. PubMed ID: 34479543
    [Abstract] [Full Text] [Related]

  • 3. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, Zhang J.
    Cardiovasc Diabetol; 2021 Jan 25; 20(1):25. PubMed ID: 33494751
    [Abstract] [Full Text] [Related]

  • 4. Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
    Ohte N, Tanaka A, Kitada S, Yamada T, Eguchi K, Teragawa H, Takeishi Y, Kodama K, Seo Y, Node K, CANDLE Trial Investigators.
    J Cardiol; 2023 Jun 25; 81(6):508-512. PubMed ID: 36481298
    [Abstract] [Full Text] [Related]

  • 5. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
    Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K.
    Cardiovasc Diabetol; 2018 May 22; 17(1):73. PubMed ID: 29788955
    [Abstract] [Full Text] [Related]

  • 6. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
    Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI.
    Cardiovasc Diabetol; 2018 Oct 08; 17(1):132. PubMed ID: 30296931
    [Abstract] [Full Text] [Related]

  • 7. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL, Xu J, Li J, Shaw W, Oh R, Pfeifer M, Butler J, Sattar N, Mahaffey KW, Neal B, Hansen MK.
    J Am Coll Cardiol; 2020 Nov 03; 76(18):2076-2085. PubMed ID: 33121714
    [Abstract] [Full Text] [Related]

  • 8. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).
    Tanaka A, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Tomiyama H, Sata M, Ueda S, Oyama JI, Kitakaze M, Murohara T, Node K, CANDLE Trial Investigators.
    ESC Heart Fail; 2020 Aug 03; 7(4):1585-1594. PubMed ID: 32349193
    [Abstract] [Full Text] [Related]

  • 9. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
    Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M.
    Cardiovasc Diabetol; 2019 Jun 05; 18(1):76. PubMed ID: 31167663
    [Abstract] [Full Text] [Related]

  • 10. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A, Inoue T, Kitakaze M, Oyama J, Sata M, Taguchi I, Shimizu W, Watada H, Tomiyama H, Ako J, Sakata Y, Anzai T, Uematsu M, Suzuki M, Eguchi K, Yamashina A, Saito Y, Sato Y, Ueda S, Murohara T, Node K.
    Cardiovasc Diabetol; 2016 Apr 04; 15():57. PubMed ID: 27044332
    [Abstract] [Full Text] [Related]

  • 11. Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: A sub-analysis of the PROTECT trial.
    Kusunose K, Imai T, Tanaka A, Doi M, Koide Y, Fukumoto K, Kadokami T, Ohishi M, Teragawa H, Ohte N, Yamada H, Sata M, Node K, PROTECT investigators.
    J Cardiol; 2024 Oct 04; 84(4):246-252. PubMed ID: 38378130
    [Abstract] [Full Text] [Related]

  • 12. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S, Yamada T, Watanabe T, Morita T, Furukawa Y, Kawasaki M, Kikuchi A, Kawai T, Seo M, Abe M, Nakamura J, Yamamoto K, Kayama K, Kawahira M, Tanabe K, Fujikawa K, Hata M, Fujita Y, Umayahara Y, Taniuchi S, Sanada S, Shintani A, Fukunami M.
    Circ Heart Fail; 2021 Mar 04; 14(3):e007048. PubMed ID: 33663235
    [Abstract] [Full Text] [Related]

  • 13. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
    Islam MN, Chowdhury MS, Paul GK, Debnath RC, Shakil SS.
    Mymensingh Med J; 2019 Apr 04; 28(2):333-346. PubMed ID: 31086148
    [Abstract] [Full Text] [Related]

  • 14. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H, Soga F, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI.
    Cardiovasc Diabetol; 2020 Jan 07; 19(1):6. PubMed ID: 31910853
    [Abstract] [Full Text] [Related]

  • 15. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2017 May 11; 16(1):63. PubMed ID: 28490337
    [Abstract] [Full Text] [Related]

  • 16. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.
    Kremastinos DT, Hamodraka E, Parissis J, Tsiapras D, Dima K, Maisel A.
    Am Heart J; 2010 Jan 11; 159(1):68-74. PubMed ID: 20102869
    [Abstract] [Full Text] [Related]

  • 17. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ.
    J Am Coll Cardiol; 2017 Aug 08; 70(6):704-712. PubMed ID: 28619659
    [Abstract] [Full Text] [Related]

  • 18. Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
    Han SW, Choi SW, Ryu KH, Kim HJ, Kim SH, Shim WJ, Cha TJ, Choi DJ, Kim YJ, Yoo BS, Kim JH, Hwang KK, Jeon H, Shin MS.
    Cardiovasc Ther; 2016 Jun 08; 34(3):172-9. PubMed ID: 27003232
    [Abstract] [Full Text] [Related]

  • 19. N-terminal B-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluationof the Evolution of New-Heart Failure Study (SCREEN-HF).
    McGrady M, Reid CM, Shiel L, Wolfe R, Boffa U, Liew D, Campbell DJ, Prior D, Krum H.
    Eur J Heart Fail; 2013 May 08; 15(5):573-80. PubMed ID: 23338855
    [Abstract] [Full Text] [Related]

  • 20. The role of N terminal pro-brain natriuretic peptide in the evaluation of left ventricular diastolic dysfunction: correlation with echocardiographic indexes in hypertensive patients.
    Ceyhan C, Unal S, Yenisey C, Tekten T, Ceyhan FB.
    Int J Cardiovasc Imaging; 2008 Mar 08; 24(3):253-9. PubMed ID: 17687631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.